SCHEMBL22309759

SCHEMBL22309759

c1ccc(-c2cc(-c3cccc(-c4cccc(-c5nc(-c6ccc7ccccc7c6)nc(-c6ccc7ccccc7c6)n5)c4)c3)nc(-c3ccccc3)n2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A1 P04798 1/20 0.63
▸ CYP1B1 Q16678 1/20 0.63
▸ MEN1 O00255 8/20 0.59
▸ KMT2A Q03164 8/20 0.59
▸ ALDH1A1 P00352 6/20 0.59
▸ MAPT P10636 5/20 0.59
▸ HPGD P15428 5/20 0.59
▸ KDM4E B2RXH2 4/20 0.59
▸ LMNA P02545 2/20 0.59
▸ GLA P06280 1/20 0.59
▸ NTSR1 P30989 1/20 0.54
▸ CYP1A2 P05177 2/20 0.53
▸ CTRC Q99895 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ MAOB P27338 3/20 0.48
▸ MAOA P21397 2/20 0.48
▸ ADORA2A P29274 1/20 0.47
▸ ADORA1 P30542 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22308550 1.00 CYP1A1 (0.63) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL22309621 1.00 CYP1A1 (0.63) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL22309914 0.98 CYP1A1 (0.61) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL22309635 0.98 CYP1A1 (0.61) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL22309612 0.98 CYP1A1 (0.61) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL22308761 0.98 CYP1A1 (0.61) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL22309012 0.98 CYP1A1 (0.60) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL22113747 0.98 CYP1A1 (0.60) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL17754440 0.97 CYP1A1 (0.59) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL22309762 0.97 CYP1A1 (0.58) CYP1A1CYP1B1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11917910-B2 Organic compound and organic electroluminescent device using the same SOLUS ADVANCED MATERIALS CO., LTD. (KR) 2024-02-27 — — US disclosed
US-11917910-B2 Organic compound and organic electroluminescent device using the same SOLUS ADVANCED MATERIALS CO., LTD. (KR) 2024-02-27 — — US disclosed
US-20200251659-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME DOOSAN CORPORATION (KR) 2020-08-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200251659-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME VDAC1, OR10J3, PIEZO1 CYP1A1 1223/4885CYP1B1 2080/4885MEN1 2484/4885
US-11917910-B2 Organic compound and organic electroluminescent device using the same VDAC1, OR10J3, PIEZO1 CYP1A1 1223/4885CYP1B1 2080/4885MEN1 2484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback